SOHO State of the Art Updates and Next Questions | The Role of Maintenance Therapy Following Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma.

Authors

Bradley Uyemura, Natalie S Callander

Published in

Clinical lymphoma, myeloma & leukemia. Jul 31, 2026. Epub Jul 31, 2026.

Abstract

Maintenance therapy has been one of the cornerstones of multiple myeloma (MM) management, aiming to prolong remission duration, delay progression, and improve survival while preserving quality of life. Following advances in induction regimens and the widespread use of autologous stem cell transplantation, the role of post-transplant maintenance therapy has evolved from interferon-based approaches to continuous therapy with immunomodulatory drugs, proteasome inhibitors, monoclonal antibodies, and more recently, bispecific antibodies. This review summarizes the modern data of maintenance therapies for MM while also discussing emerging approaches with minimal residual disease-based strategies and additional novel agents.

PMID:
42754492
Bibliographic data and abstract were imported from PubMed on 18 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.